Serum L C3-II levels in type 2 diabetic patients with impaired renal functions        
Yazarlar (4)
Shahab Ahmed Salıh Gezh
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Doç. Dr. Köksal DEVECİ Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Doç. Dr. Hakan ŞIVGIN Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Dr. Öğr. Üyesi Figen GÜZELGÜL Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Makale Türü Özgün Makale
Makale Alt Türü SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale
Dergi Adı Cytokine
Dergi ISSN 1043-4666 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Dergi Grubu Q2
Makale Dili Türkçe
Basım Tarihi 09-2024
Cilt No 181
Sayı 1
DOI Numarası 10.1016/j.cyto.2024.156683
Makale Linki https://doi.org/10.1016/j.cyto.2024.156683
Özet
This study was designed to evaluate serum LC3-II, BCL-2, IL-1β, TGF-β1, and podocin levels in. type 2 diabetes (T2DM) patients with renal dysfunction. 176 Turkish subjects were enrolled, of whom 26 were healthy, and 150 had T2DM. were classified according to albumin urea ratio: 88 patients had macroalbuminuria, 20. patients had microalbuminuria, and 42 had normoalbuminuria. T2DM patients were also. classified into three groups according to proteinuria and eGFR stages. Increased serum LC3-II levels in patients with T2DM with increased urinary albumin. extraction and impaired renal functions. There was a strong relationship between serum. LC3-II levels and serum BCL-2, IL-1β, TGF-β1, and Podocin levels. The efficiency of LC3- II as a diagnostic biomarker in the differential diagnosis of DM patients with. macroproteinuria from DM patients with normoproteinuria was 75.4%. It was thought that increased serum LC3-II levels in T2DM patients with impaired renal. functions may cause renal podocyte damage. In these patients, serum LC3-II levels can be. evaluated as a new biomarker to follow the development of renal damage.
Anahtar Kelimeler
Autophagy | BCL-2 | DKD | LC3-II | Podocin | Proteinuria